Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Accured Expenses (2020 - 2026)

Cytek Biosciences filings provide 6 years of Change in Accured Expenses readings, the most recent being $4.7 million for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 60.28% to $4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 585.92% increase, with the full-year FY2025 number at $4.0 million, up 585.92% from a year prior.
  • Change in Accured Expenses hit $4.7 million in Q4 2025 for Cytek Biosciences, up from -$1.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $8.9 million in Q4 2021 to a low of -$4.8 million in Q2 2024.
  • Median Change in Accured Expenses over the past 5 years was $462500.0 (2021), compared with a mean of $1.1 million.
  • The widest YoY moves for Change in Accured Expenses: up 2368.91% in 2024, down 360.86% in 2024.
  • Cytek Biosciences' Change in Accured Expenses stood at $8.9 million in 2021, then crashed by 47.72% to $4.6 million in 2022, then crashed by 97.44% to $119000.0 in 2023, then soared by 2368.91% to $2.9 million in 2024, then skyrocketed by 60.28% to $4.7 million in 2025.
  • The last three reported values for Change in Accured Expenses were $4.7 million (Q4 2025), -$1.4 million (Q3 2025), and $2.8 million (Q2 2025) per Business Quant data.